Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. | CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing